Treatment of inflammatory breast cancer with combination chemotherapy and mastectomy versus breast conservation

• Published in: Cancer Vol. 61; no. 6; pp. 1096 - 1103
• Main Authors: Brun, B., Otmezguine, Y., Feuilhade, F., Julien, M., Lebourgeois, J. P., Calitchi, E., Roucayrol, A. M., Ganem, G., Huart, J., Pierquin, B.
• Format: Journal Article
• Language: English
• Published: New York Wiley Subscription Services, Inc., A Wiley Company 15.03.1988; Wiley-Liss
• Subjects: Adult; Aged; Antineoplastic agents; Antineoplastic Combined Chemotherapy Protocols - therapeutic use; Biological and medical sciences; Brachytherapy; Breast Neoplasms - drug therapy; Breast Neoplasms - radiotherapy; Breast Neoplasms - surgery; Breast Neoplasms - therapy; Carcinoma - drug therapy; Carcinoma - radiotherapy; Carcinoma - surgery; Carcinoma - therapy; Chemotherapy; Combined Modality Therapy; Cyclophosphamide - administration & dosage; Doxorubicin - administration & dosage; Female; Fluorouracil - administration & dosage; Humans; Mastectomy; Medical sciences; Middle Aged; Pharmacology. Drug treatments; Prognosis; Vincristine - administration & dosage; Antineoplastic agent; Human; Polychemotherapy; Surgery; Mastectomy; Tumor; Anthracyclins; Combined treatment; Mammary gland; Radiotherapy; Inflammatory disease
• ISSN: 0008-543X; 1097-0142
• DOI: 10.1002/1097-0142(19880315)61:6<1096::AID-CNCR2820610608>3.0.CO;2-Y

Twenty‐six consecutive patients with nonmetastatic inflammatory breast cancer (IBC), were treated in a single institution using the same protocol, and all were followed for at least 48 months. The first phase of treatment consisted of two monthly cycles of combination chemotherapy with Adriamycin (Adria Laboratories, Columbus, OH), vincristine, cyclophosphamide and 5‐fluorouracil. Local treatment was then undertaken using in all cases a cobalt 60 beam to deliver 45 Gy to the entire mammary gland and lymph‐draining areas. Local treatment was completed either by mastectomy, or by conservation of the breast and interstitial irradiation of the primary tumor site. Chemotherapy was resumed after completion of local treatment for a total of 6 cycles. Metastatic disease occurred in 19 of 26 patients from 8 to 55 months; five patients are alive and free of disease from 48 to 81 months. Failure to control local disease or local recurrences was noted in two of ten patients undergoing mastectomy, and in seven of 13 patients with conservation of the breast. While this difference is not statistically significant we concluded that methods of breast conservation which limit the high dose volume to the tumor site do not assure local control in IBC. The median disease‐free survival and overall survival of 12 and 31 months, respectively, are not satisfactory. Better systemic treatment is needed.